$5.48 Billion is the total value of Avoro Capital Advisors LLC's 43 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 14.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Sell | HORIZON THERAPEUTICS PLC | $683,865,000 | -31.7% | 6,500,000 | -30.1% | 12.48% | -26.8% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $543,612,000 | -17.1% | 3,030,000 | -0.2% | 9.92% | -11.1% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $480,155,000 | +18.7% | 9,450,000 | +10.5% | 8.77% | +27.3% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $437,822,000 | -41.2% | 5,325,000 | +4.9% | 7.99% | -36.9% |
| ARGX | Buy | ARGENX SEsponsored adr | $395,714,000 | +17.1% | 1,255,000 | +30.1% | 7.22% | +25.6% |
| XBI | Buy | SPDR SERIES TRUST - S&P BIOTECHetf | $274,134,000 | +133.2% | 3,050,000 | +190.5% | 5.00% | +150.1% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $258,192,000 | -4.0% | 2,200,000 | +10.0% | 4.71% | +2.9% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $244,906,000 | -13.0% | 3,135,000 | +0.3% | 4.47% | -6.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $233,999,000 | -5.4% | 3,035,000 | +8.4% | 4.27% | +1.5% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $212,277,000 | +16.4% | 1,300,000 | +20.9% | 3.88% | +24.9% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $194,135,000 | -9.1% | 20,500,000 | +10.8% | 3.54% | -2.6% |
| SGEN | New | SEAGEN INC | $189,426,000 | – | 1,315,000 | +100.0% | 3.46% | – |
| XENE | XENON PHARMACEUTICALS INC | $152,391,000 | -2.1% | 4,985,000 | 0.0% | 2.78% | +5.0% | |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $151,931,000 | -8.3% | 9,125,000 | +5.2% | 2.77% | -1.6% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $139,821,000 | +15.8% | 1,425,000 | 0.0% | 2.55% | +24.2% | |
| ISEE | IVERIC BIO INC | $122,018,000 | +0.7% | 7,250,000 | 0.0% | 2.23% | +8.0% | |
| KURA | Buy | KURA ONCOLOGY INC | $77,184,000 | +37.8% | 4,800,000 | +20.0% | 1.41% | +47.8% |
| KRYS | Buy | KRYSTAL BIOTECH INC | $66,873,000 | +101.3% | 1,005,000 | +111.6% | 1.22% | +116.1% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $55,101,000 | +7.3% | 2,275,000 | +3.4% | 1.01% | +15.1% |
| GLUE | MONTE ROSA THERAPEUTICS INC | $46,426,000 | -31.3% | 3,311,434 | 0.0% | 0.85% | -26.3% | |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $45,804,000 | +35.3% | 2,200,000 | +50.2% | 0.84% | +45.1% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $38,592,000 | -18.9% | 2,220,500 | +2.1% | 0.70% | -13.0% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $35,889,000 | +2.5% | 2,222,222 | +35.8% | 0.66% | +9.9% |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $34,554,000 | -1.0% | 816,500 | +48.5% | 0.63% | +6.2% |
| MNKD | MANNKIND CORP | $32,384,000 | -15.8% | 8,800,000 | 0.0% | 0.59% | -9.6% | |
| CBAY | CYMABAY THERAPEUTICS INC | $32,033,000 | -8.0% | 10,300,000 | 0.0% | 0.58% | -1.3% | |
| AADI BIOSCIENCES INC | $31,045,000 | -29.7% | 1,829,402 | 0.0% | 0.57% | -24.6% | ||
| BCRX | New | BIOCRYST PHARMACEUTICLAS INC | $30,488,000 | – | 1,875,000 | +100.0% | 0.56% | – |
| Sell | MARINUS PHARMACEUTICALS INC | $29,453,000 | -23.4% | 3,150,000 | -2.6% | 0.54% | -17.7% | |
| MRSN | MERSANA THERAPEUTICS INC | $27,132,000 | -35.9% | 6,800,000 | 0.0% | 0.50% | -31.2% | |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $24,011,000 | -17.9% | 1,300,000 | +5.7% | 0.44% | -12.0% |
| PRAX | Buy | PRAXIS PRECISION MEDICINES INC | $21,952,000 | -37.4% | 2,150,000 | +20.8% | 0.40% | -32.8% |
| Buy | DICE THERAPEUTICS INC | $20,565,000 | +44.4% | 1,075,000 | +91.1% | 0.38% | +55.0% | |
| AMRN | AMARIN CORP PLCsponsored adr | $19,740,000 | -2.4% | 6,000,000 | 0.0% | 0.36% | +4.7% | |
| RARE | New | ULTRAGENYX PHARMACEUTICAL INC | $16,703,000 | – | 230,000 | +100.0% | 0.30% | – |
| Sell | NUVALENT INC | $14,577,000 | -20.9% | 1,049,471 | -4.8% | 0.27% | -15.3% | |
| TANGO THERAPEUTICS INC | $11,749,000 | -30.7% | 1,550,000 | 0.0% | 0.21% | -26.0% | ||
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $11,406,000 | -15.5% | 1,670,000 | 0.0% | 0.21% | -9.6% | |
| IO BIOTECH INC | $9,580,000 | -6.5% | 2,055,883 | 0.0% | 0.18% | +0.6% | ||
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $9,105,000 | -25.6% | 6,950,000 | 0.0% | 0.17% | -20.2% | |
| AMTI | New | APPLIED MOLECULAR TRANS INC | $7,746,000 | – | 1,030,000 | +100.0% | 0.14% | – |
| FENC | FENNEC PHARMACEUTICALS INC | $6,720,000 | +27.3% | 1,200,000 | 0.0% | 0.12% | +36.7% | |
| GNCA | GENOCEA BIOSCIENCES INC | $6,355,000 | +7.7% | 5,084,184 | 0.0% | 0.12% | +16.0% | |
| SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -300,000 | -100.0% | -0.05% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -1,235,000 | -100.0% | -1.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC. | 39 | Q2 2024 | 17.9% |
| MIRATI THERAPEUTICS INC. | 36 | Q4 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 34 | Q2 2024 | 8.0% |
| SAREPTA THERAPUTICS INC | 31 | Q2 2024 | 14.8% |
| ASCENDIS PHARMA | 31 | Q2 2024 | 9.1% |
| ARGENX SE | 29 | Q2 2024 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 29 | Q2 2024 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 26 | Q4 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 25 | Q2 2024 | 7.7% |
| XENON PHARMACEUTICALS INC | 25 | Q2 2024 | 3.6% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Spyre Therapeutics, Inc. | April 23, 2024 | 1,839,138 | 5.1% |
| AMICUS THERAPEUTICS, INC. | February 14, 2024 | 27,400,000 | 9.3% |
| Apellis Pharmaceuticals, Inc. | February 14, 2024 | 13,411,111 | 9.9% |
| Ascendis Pharma A/S | February 14, 2024 | 3,755,555 | 6.5% |
| BIOCRYST PHARMACEUTICALS INC | February 14, 2024 | 13,050,000 | 6.4% |
| CymaBay Therapeutics, Inc. | February 14, 2024 | 16,337,739 | 10.0% |
| IO Biotech, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Krystal Biotech, Inc. | February 14, 2024 | 2,565,555 | 9.1% |
| Kymera Therapeutics, Inc. | February 14, 2024 | 3,775,000 | 6.8% |
| MADRIGAL PHARMACEUTICALS, INC. | February 14, 2024 | 2,288,888 | 9.9% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-27 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.